BRPI0813553A2 - composições farmacêuticas e métodos para tratamento de distúrbios do olho seco - Google Patents

composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Info

Publication number
BRPI0813553A2
BRPI0813553A2 BRPI0813553A BRPI0813553A BRPI0813553A2 BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2 BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
dry eye
eye disorders
treating dry
Prior art date
Application number
BRPI0813553A
Other languages
English (en)
Inventor
Rodney Beals Channing
Woldemussie Elizabeth
John Gukasyan Hovhannes
Ma Jingwen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0813553A2 publication Critical patent/BRPI0813553A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0813553A 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco BRPI0813553A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94921607P 2007-07-11 2007-07-11
US6003208P 2008-06-09 2008-06-09
PCT/IB2008/001819 WO2009007839A1 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders

Publications (1)

Publication Number Publication Date
BRPI0813553A2 true BRPI0813553A2 (pt) 2017-05-09

Family

ID=39925011

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813553A BRPI0813553A2 (pt) 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Country Status (15)

Country Link
US (2) US8541426B2 (pt)
EP (1) EP2175858B1 (pt)
JP (2) JP5649270B2 (pt)
KR (2) KR101258316B1 (pt)
CN (1) CN101743009A (pt)
AR (1) AR067495A1 (pt)
AU (1) AU2008273804B2 (pt)
BR (1) BRPI0813553A2 (pt)
CA (1) CA2691914C (pt)
ES (1) ES2523303T3 (pt)
NZ (1) NZ582188A (pt)
RU (1) RU2445098C2 (pt)
TW (1) TWI364281B (pt)
WO (1) WO2009007839A1 (pt)
ZA (1) ZA201000991B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
AU2010239396B2 (en) * 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US9510972B2 (en) * 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016064078A1 (ko) * 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
CN104857287B (zh) * 2015-04-21 2021-05-11 湖南中医药大学 一种治疗干眼症的中药滴眼液及其制备方法
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SG11202006782YA (en) 2018-01-31 2020-08-28 Twi Pharmaceuticals Inc Topical formulations comprising tofacitinib
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
US12263115B2 (en) 2018-09-11 2025-04-01 Sight Sciences, Inc. Forceps treatment systems
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
JP7722931B2 (ja) * 2019-12-27 2025-08-13 ロート製薬株式会社 水性組成物
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN114948991A (zh) * 2021-02-26 2022-08-30 复旦大学 氢化镁在制备防治干眼病相关眼表炎症药物中的应用
JP2025014078A (ja) * 2021-11-30 2025-01-29 興和株式会社 新規ニコチンアミド化合物及びその用途
KR20240159823A (ko) * 2023-04-28 2024-11-06 비바비젼 바이오테크 엘티디 비감염성 염증성 질환의 치료를 위한 안과 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5747474A (en) 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1162974A1 (en) 1999-03-19 2001-12-19 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
US20020132767A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
PY0228255A (es) 2001-12-06 2004-06-01 Pfizer Prod Inc Compuestos cristalinos novedosos
RU2285511C2 (ru) * 2004-10-13 2006-10-20 НИИ ГБ им. Гельмгольца Средство для лечения синдрома сухого глаза
RU2290923C2 (ru) * 2005-03-04 2007-01-10 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения синдрома сухого глаза
JP2008534689A (ja) * 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP1913000B1 (en) 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en) * 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
JP2007314326A (ja) * 2006-05-26 2007-12-06 Mitsubishi Heavy Ind Ltd チョッパ折り方法及び装置
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders

Also Published As

Publication number Publication date
CA2691914A1 (en) 2009-01-15
NZ582188A (en) 2012-03-30
WO2009007839A1 (en) 2009-01-15
KR20120115413A (ko) 2012-10-17
AR067495A1 (es) 2009-10-14
US8541426B2 (en) 2013-09-24
TW200911265A (en) 2009-03-16
ES2523303T3 (es) 2014-11-24
US20100267751A1 (en) 2010-10-21
TWI364281B (en) 2012-05-21
JP2013147517A (ja) 2013-08-01
RU2009149687A (ru) 2011-07-10
US20130303557A1 (en) 2013-11-14
JP5649270B2 (ja) 2015-01-07
EP2175858A1 (en) 2010-04-21
RU2445098C2 (ru) 2012-03-20
AU2008273804B2 (en) 2014-07-10
JP2009046470A (ja) 2009-03-05
CA2691914C (en) 2012-06-26
CN101743009A (zh) 2010-06-16
KR20100029823A (ko) 2010-03-17
ZA201000991B (en) 2010-12-29
AU2008273804A1 (en) 2009-01-15
EP2175858B1 (en) 2014-09-10
KR101258316B1 (ko) 2013-04-30

Similar Documents

Publication Publication Date Title
BRPI0813553A2 (pt) composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0719918A2 (pt) Tratamento para olho seco usando-se testosterona e progestagênio
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0916323A2 (pt) composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0819678A2 (pt) método para tratar cmt e distúrbios relacionados
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
BR112014016389A2 (pt) composições e métodos para o tratamento de doenças e distúrbios hepáticos
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]